BioLineRx BLRX Cash Flow Statement (2011-2026)

NASDAQ BLRX
$2.71 +0.02 (+0.74%)
As of: Sep 4, 2026 · 12:23 PM EDT
Reported Financials

BioLineRx Quarterly Cash Flow Statement

Periods 57 quarters
Latest Jun 2026

BioLineRx reported cash from operations of -$3.22M and free cash flow of -$3.22M for the quarter ended Jun 2026. This cash flow statement covers 57 quarters of results from Sep 2011 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2011 Dec2011 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-39.78M49.80M-5.83M-7.14M-31.59M-6.63M-7.39M-8.14M-77.44M-18.72M-3.33M-3.15M-3.33M0.39M-1.68M-1.54M-1.53M-2.80M-2.55M-3.23M
Share-based Compensation
0.27M0.39M0.26M0.33M0.61M1.04M0.43M0.48M0.47M0.93M0.53M0.44M0.32M-0.15M0.19M0.05M0.10M0.05M0.08M0.08M
Gains from Investment Securities
-0.80M-2.15M-1.25M-0.42M-1.10M-3.65M3.04M7.80M3.12M-2.91M-4.44M-8.40M-0.72M-5.40M-8.31M1.90M-1.13M-1.05M-0.44M0.68M
Non-cash Items
0.70M-1.20M-0.66M1.15M-1.83M0.05M4.15M8.86M6.12M18.88M-13.41M-11.81M-4.00M-5.42M-7.72M3.76M-1.13M-0.96M0.31M1.12M
Cash from Operations
-5.01M-5.50M-5.59M-6.29M-8.68M-5.68M-8.02M-9.68M-9.90M4.99M-14.11M-11.33M-9.82M-8.61M-2.59M-0.18M-2.11M-3.20M-2.28M-3.22M
Depreciation, Depletion & Amortization
Amortization of Deferred Charges
0.03M0.70M
Depreciation & Amortization (CF)Depreciation & Amortization
0.17M0.17M0.17M0.14M0.15M0.19M0.26M0.20M0.22M0.71M0.90M0.48M0.84M1.85M0.17M0.12M0.06M0.09M0.08M
Change in Working Capital
Change in Receivables
-2.47M-0.35M-0.43M1.14M1.01M1.39M0.08M-0.05M0.05M-0.05M
Change in Inventory
-1.35M-0.60M-0.94M-0.74M0.09M0.40M-0.17M0.47M0.67M0.03M-0.01M-0.01M
Change in Account Payables
0.18M0.23M0.25M1.42M-1.29M1.50M0.39M-0.11M2.13M3.10M-3.51M-2.12M-0.59M0.71M-2.51M0.03M-0.57M-0.43M1.94M-0.67M
Other Working Capital Changes
2.04M-0.40M-0.05M1.04M-1.11M-0.52M-0.05M-0.63M0.35M-0.64M-0.13M-17.84M17.59M0.34M-0.13M1.48M-1.76M1.71M-0.06M0.86M
Investing Activities
Capital Expenditures
0.00M-0.06M-0.02M-0.04M-0.01M0.10M-0.03M-0.07M-0.00M-0.02M-0.03M-0.03M0.01M-0.01M
Change in Acquisitions & Divestments
-12.00M-8.00M-7.00M-2.00M-27.00M-8.00M-5.50M-0.51M-7.88M-33.71M16.72M-37.28M-5.79M-12.31M-12.51M-4.21M-7.62M-5.18M-2.48M
Cash from Investing Activities
0.04M4.00M5.05M10.03M-14.94M3.86M6.64M11.10M4.10M-20.39M16.69M-8.64M10.18M11.16M-8.18M-3.70M3.67M-0.34M2.70M6.35M
Financing Activities
Other financing activities
0.00M2.53M0.40M-0.01M
Debt Issuance and Repayment
Long-Term Debt Issuances
-0.85M2.50M-0.90M-0.92M11.49M-12.51M-0.80M-0.74M-0.77M-0.78M-0.91M-11.97M-1.12M-1.12M-1.12M-1.14M-1.12M-1.12M
Long-Term Debt Repayments
-0.85M-0.87M
Change in Capital Stock
Net Equity Issued and Repurchased
Misc.
Cash from Financing Activities
1.57M0.17M-0.94M-0.69M22.72M-0.65M-0.05M-0.13M3.50M11.74M-0.89M23.88M-1.22M-1.11M9.45M1.60M-0.92M-1.25M-1.18M-1.14M
Exchange Rate Effect
-0.01M0.24M-0.06M-0.50M0.01M1.16M-0.10M-0.25M-0.07M0.64M0.05M-0.27M0.08M0.12M-0.08M0.43M0.07M-0.97M0.01M0.13M
Change in Cash
-3.40M-1.33M-1.48M3.05M-0.90M-2.47M-1.42M1.28M-2.31M-3.66M1.68M3.90M-0.87M1.44M-1.32M-2.28M0.65M-4.79M-0.76M1.99M
Beginning Cash Balance
16.83M16.83M12.99M12.99M12.99M12.99M10.59M10.59M10.59M10.59M4.25M4.25M4.25M4.25M10.44M10.44M10.44M10.44M3.25M3.25M
Free Cash Flow
-5.02M-5.44M-5.57M-6.25M-8.67M-5.79M-7.98M-9.62M-9.90M5.01M-14.08M-11.30M-9.82M-8.62M-2.59M-0.18M-2.11M-3.20M-2.27M-3.22M
Net Cash Flow
-3.40M-1.33M-1.48M3.05M-0.90M-2.47M-1.42M1.28M-2.31M-3.66M1.68M3.90M-0.87M1.44M-1.32M-2.28M0.65M-4.79M-0.76M1.99M